Home Page Image

REMEDIC is supported by

the European Science Foundation

1st European Interdisciplinary Summit on Cell-Based ATMPs

will be held in Vienna, Austria,
May 02 - 03, 2013





Useful links (.pdf) to regulatory aspects and registries. Human stem cell regulations and legislation in Europe (.pdf)



Regenerative medicine, a rapidly evolving and exciting field, can be defined as the process of creating living, functional tissues to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. This can be done through a variety of approaches including the replacement of tissue function with synthetic constructs (artificial organs) and using cellular therapies such as stem cells or genetically modified cells to generate new tissues and organs.

Recent advances in stem cell technologies, including for example the ability to induce human pluripotent stem (iPS) cells, mark a new era for regenerative medicine. Stem cells have an almost unlimited proliferation potential accompanied by an ability to differentiate. Thus, hematopoietic stem cells (HSCs – that give rise to the various blood cell types, including neutrophils and erythrocytes) and mesenchymal stem (or stromal) cells (MSCs – that give rise to many cell types, including adipocytes and chondrocytes) form an essential element in regenerative (or reparative) medicine, including guided regeneration.

As our knowledge advances, the frontiers of regenerative medicine are rapidly expanding. Regenerative medicine provides new insights in areas including cellular proliferation, effects of humoral and matrix signaling on cells, angiogenesis, tissue remodeling, naïve and adaptive immunity and other basic processes in cell biology. Still, regenerative medicine is in its infancy and to advance progress in this important field, national funding agencies from 13 European countries have joined forces to launch a cross-disciplinary Research Networking Programme, REMEDIC, to identify where the frontiers and future needs are in this complex multidisciplinary high-technology field, by networking researchers and clinicians across Europe.



1. To facilitate the exchange of ideas and know-how across disciplines in the area of mesenchymal (stromal) and other stem cells.

2. To review the regulatory laws, rules and standards governing the use of regenerative medicine.

3. To map the unmet population, academia and company needs in regenerative medicine and the current R&D resources (e.g. instruments, analysis techniques).

4. To assist researchers in the field of regenerative medicine in preparing cross-disciplinary coordinated research projects.



Press release (19 June 2008)




Five years, from May 2008 to April 2013 (07-RNP-128).



European collaborative projects:

EU Cost project: MPNS COST Action MP1005 "NAMABIO" : "From nano to macro biomaterials (design, processing,  characterization, modeling) and applications to stem cells  regenerative orthopedic and dental medicine"

FP 7 Project "REBORNE" : "Regenerating Bone Defects using New biomedical Engineering approaches"

EU Cost project: Cost Action BM0806 Histamine H4 Receptor Research HARR4-Eu COST

EU 7th framework program NMP-2009-2.3-1 “Biomimetic gels and polymers for tissue repair”. "GAMBA" : "Gene Activated Matrices for Bone and Cartilage Regeneration in Arthritis"

The Danish Council for Strategic Research project IMR : “Individualized musculoskeletal regeneration and reconstruction


You are welcome to read more about us in our home page.
Chair Yrjö T. Konttinen, Professor of Medicine